Microglial activation is a key pathological feature of Alzheimer's disease (AD). PET 
Introduction
Alzheimer's Disease (AD) is a rapidly growing global health issue [1] . In 2016, the total cost of caring for AD patients, in the United States alone, was estimated to be $236 billion. By 2050 this figure is projected to grow to approximately $1.1 trillion [2] . At present, there are no approved disease-modifying treatments to slow or halt the progression of this disease. Although we are beginning to understand more about the pharmacological requirements for treating AD, every new drug that has been developed over the past decade has failed to achieve predetermined endpoints in mild-to-moderate AD clinical trials [3] [4] [5] [6] [7] . One possible reason for these disappointing results is the relatively small role that appropriate biomarkers have played in both preclinical and clinical drug discovery and development.
While there have been sizeable efforts toward the development of amyloid-and tau-based biomarkers that are relevant to both mouse models
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International Publisher and patients (e.g., cerebrospinal fluid, blood, imaging), translational endpoints that mirror the significant neuroinflammatory aspect of AD remain limited.
Increasing evidence suggests that neuroinflammation is an important early event in the pathophysiology of AD [8, 9] , playing both beneficial and detrimental roles, ranging from trophic support, amyloid clearance and tissue remodeling, to increased production of neurotoxic pro-inflammatory cytokines. Multiple studies have shown that neuroinflammation is present at the pre-plaque stage of pathology [10, 11] and that it could be a prelude to AD [12] . Additionally, it seems that early anti-inflammatory intervention can profoundly impact the incidence and progression of AD [11, 13, 14] . Due to the complex nature and nuanced role of neuroinflammation in different stages of AD, specific imaging techniques to visualize and track neuroinflammation non-invasively could potentially provide critical insights that will help improve understanding and also serve to monitor the effects of therapeutic interventions.
Positron emission tomography (PET) imaging of the translocator protein 18 kDa (TSPO) is a strategy used to detect neuroinflammation non-invasively in vivo [15] . TSPO, formerly known as the peripheral benzodiazepine receptor (PBR), was initially characterized as a high affinity binding site for diazepam, and is believed to be involved in transporting cholesterol from the outer to inner mitochondrial membrane (i.e., the rate limiting step of steroid biosynthesis) [16] . While TSPO is densely distributed in most peripheral organs and only moderately expressed in the healthy brain, it is upregulated under neuroinflammatory conditions. The predominant cell type expressing TSPO at regions of central nervous system pathology are activated microglia. TSPO-PET imaging can therefore serve as a useful index of microglial activation, and thus neuroinflammation. There are several TSPO radiotracers available [17] , however each have their limitations. For example, TSPO radioligand [ 11 C]PK11195 has been used extensively for the last few decades, and although it has provided unprecedented in vivo information concerning microglial activation in AD [18] [19] [20] , its poor brain permeability, high plasma protein binding, and short half-life due to its carbon-11 radiolabel (t½ = 20 min) have limited its overall clinical utility [21] . Second generation TSPO-PET radiotracers have been developed with higher affinities and some with longer half-lives (i.e., radiolabeled with fluorine-18, t½ = 110 min) compared to [ 11 for detecting neuroinflammation in AD patients, however the results are yet to be reported. One limitation of using second generation TSPO radiotracers for clinical studies is their apparent inter-and intra-subject variability due to a polymorphism in the gene encoding TSPO -giving rise to low-affinity, mixed-affinity, and high-affinity binders [27] . This phenomena, while not observed in rodents or non-human primates, necessitates genotyping patients prior to a TSPO-PET scan to help with quantitation of ligand binding [28] .
Flutriciclamide ([ 18 F]GE-180) is a new fluorine-18 labeled, second-generation, TSPO-specific radioligand [29] with high affinity (Ki = 0. 87 nM), excellent in vivo target-to-background binding, and encouraging first-in-man imaging data [30] . Recent studies directly comparing [ 18 [35] in a well-characterized mouse model of AD [36] . Results from this study are critical for determining the sensitivity and potential utility of [ 18 F]GE-180-PET as a translatable imaging biomarker for detecting neuroinflammation-related AD pathology and therapeutic response.
Materials and Methods

Study Design
We selected the Thy1-hAPP Lond/Swe (APP L/S ) mouse model of AD for the current studies since it is a well-characterized model of AD pathology [37] that we have previously used to evaluate novel therapeutics, including LM11A-31, at different stages of disease, albeit without in vivo imaging endpoints [36, 38] . In this mouse model, mature amyloid plaques occur in the frontal cortex as early as 3-4 months of age, and in the hippocampus at 5-7 months [37] . Our earlier work (involving imaging APP L/S mice without a therapeutic component) demonstrated that [ 18 F]PBR06 can detect elevated microglial activation in APP L/S mice as young as 9-10 months using ex vivo autoradiography [39] . Due to this, we began our head-to-head PET imaging comparison studies in APP L/S mice of a similar age. Likewise, we designed the therapy monitoring studies based upon our previous experiments with LM11A-31 in APP L/S mice of similar ages (i.e., we aimed to commence therapy after pathology was present), while also considering which age we might be able to detect differences in TSPO-PET signal between APP L/S and wild-type mice. A minimum of 5-6 experimental replicates were recorded for all [ 18 F]GE-180 dynamic PET data, including blocking studies with PK11195. Six to seven animals per group were used for the head-to-head comparison studies and seven to eleven animals were used for therapy-monitoring studies involving PET imaging and ex vivo autoradiography, calculated with 90% power and a 5% significance level. For therapy monitoring studies, APP L/S and wild-type littermates were randomized into vehicle or LM11A-31 treatment groups according to their baseline [ 18 F]GE-180 PET signal (uptake in cortex and hippocampus) such that there were no significant differences in those parameters between different treatment groups. All experiments and analyses were performed blind to genotype and test compound.
General
If not otherwise stated, chemicals were purchased from commercial sources and used without further purification. Radiochemical yields and doses for animal studies were measured using CRC-15 PET dose calibrator (Capintec). PET imaging of mice was performed using a microPET/CT hybrid scanner (Inveon, Siemens) and MR imaging was performed using a 7 Tesla (7T) Varian Magnex Scientific MR scanner. The PET system can deliver ~1.5-2.0 mm spatial resolution, and a maximum field of view of 10cm x 30cm. OSEM3D/MAP reconstruction yields uniform spatial resolution in all directions, with an average FWHM of 1.656 ± 0.06mm. All PET images were reconstructed using 2 iterations of 3-dimensional ordered subsets expectation maximization algorithm (12 subsets) and 18 iterations of the accelerated version of 3D-MAP (i.e., FASTMAP) -matrix size of 128 × 128 × 159. Attenuation correction derived from the CT image was applied to the PET dataset.
Animals
All experiments involving animals were in accordance with protocols approved by the Institutional Animal Care and Use Committee of Stanford University and were performed based on the NIH Guide for the Care and Use of Laboratory Animals. As stated in the Study Design section, we used the Thy1-hAPP Lond/Swe (APP L/S ) mouse model of AD, transgenic line 41 mice over-expressing human APP751 containing the London (V717I) and Swedish (K670M/N671L) mutations under the control of the Thy1 promoter, which is expressed postnatally [37] . Mice were maintained on a C57BL/6J background and housed individually under a 12-hour light/dark schedule with ad libitum access to food and water. The presence or absence of the mutant APP transgene is referred to as APP L/S and wild-type (wild-type), respectively. All APP L/S and wild-type mice used for these studies were age-matched. The mean weights of mice (at age 8.5-10.0 months) in each treatment group ± standard deviation were as follows: wt-vehicle = 32.47 ± 4.01g; APP L/S -vehicle = 30.14 ± 4.63g; wt-LM11A-31 = 33.61 ± 3.53g; APP L/S -LM11A-31 = 30.51 ± 3.26g. There were no significant differences in weight between these four groups as determined by one-way ANOVA. Upon study completion, mice aged 8.5-10.0 months old were deeply anesthetized with 2.0-3.0% isoflurane gas and transcardially perfused with 50 mL saline (i.e., 0.9% sodium chloride solution). A subset of brains were processed for autoradiography and immunohistochemistry -i.e., half of each brain was taken for ex vivo autoradiography and the other half was used for histological studies, so that autoradiography and immunostaining could be performed using brain tissue from the exact same mice. For immunohistochemistry, half-brains were post-fixed with 4% paraformaldehyde in 0.1 M PBS, PH 7.4 for 24 hours at 4 °C, then cryoprotected in 30% sucrose in 0.1 M PBS for 48 hours.
Treatment with P75 Ligand, LM11A-31
is an isoleucine derivative (MW 243.3); for pharmacological characterization and structure see [35, 40] . LM11A-31 was synthesized by Ricerca Biosciences (Painesville, OH) at >97% purity as assessed by liquid chromatography/mass spectroscopy. Bioactivity was assessed by increased hippocampal neuron survival cell culture as previously described [40] . APP L/S and wild-type littermates were randomized into vehicle or LM11A-31 treatment groups according to their baseline [ 18 F]GE-180 PET signal, as described in the Study Design section of this manuscript. LM11A-31 was administered at 50 mg/kg/day once daily, 6 days a week (for 3 months), in sterile water by oral gavage following a 4-hour fasting period. Vehicle-treated mice received equivalent volume per weight of sterile water following same schedule. Male mice were treated via oral gavage beginning at 5.5-7.0 months of age for a total of 3 months.
Radiosynthesis
[ 18 F]GE-180 was synthesized via nucleophilic aliphatic substitution as previously described [29] . Minor modifications include the use of a TRACERlab FXF-N automated module for synthesis and the addition of ascorbic acid (0.1 mg/mL) to aqueous HPLC solvent to prevent radiolysis. The overall synthesis time was 72 min and radiochemical purity was 99.8 ± 0.2%, while the non-decay-corrected radiochemical yield and specific radioactivity was 13.8 ± 1.4% and 125 ± 22 GBq/μmol at EOB (n = 12), respectively. [ 18 F]PBR06 was synthesized as previously described [41] , with a non-decay-corrected radiochemical yield, radiochemical purity, and specific radioactivity of 2.34 ± 0.42%, 97.8 ± 0.7% and 147.81 ± 12.43 GBq/μmol at EOB (n = 3), respectively.
In Vivo Imaging Studies
Brain MR images were acquired to provide an anatomical reference frame to enable accurate identification of regions of interest (ROIs) -cortex and hippocampus -and for visualization of PET images in the context of brain structures. Mice were scanned with a dedicated small animal 7T Magnex Scientific MR scanner with custom-designed pulse sequences and radiofrequency (RF) coils using standard methods. For each MR scan, mice were anesthetized using isoflurane gas (2.0-3.0% for induction and 1.5-2.5% for maintenance). Coronal brain images were acquired using T2-weighted fast spin echo sequences (TE/TR 58.5 ms / 4,000 ms), 9 NEX, a 256 × 256 matrix, 3 cm field-of-view, slice thickness of 500 µm, and a total imaging time of 19 min.
For PET imaging, mice were anesthetized using isoflurane gas (2.0-3.0% for induction and 1.5-2.5% for maintenance). A CT image was acquired just before each PET scan to provide an anatomic reference frame for the respective PET data. Acquisition of dynamic PET data was commenced just prior to intravenous administration of [ 18 PET imaging studies, we used our previously reported optimized timing and acquisition/analysis protocols (i.e., 10 min static scans were acquired 40 min after tracer administration) [39] . PET and CT image files were co-registered and analyzed with VivoQuant image analysis software (version 2.0, inviCRO). For VivoQuant analyses, a 3-dimensional mouse brain atlas was fitted inside the skull of each mouse (as per their CT image) and radioactivity concentrations were obtained using automated ROIs for cerebellum, cortex, corpus callosum, hippocampus, hypothalamus, midbrain, medulla, olfactory, pallidum, pons, striatum, thalamus, ventricles, and white matter (Fig. S2) . Cortex, hippocampus, and thalamus, were further segmented into slices so that we could obtain ROIs for specific parts of these structures -i.e., caudal-thalamus (cThal) versus rostral-thalamus (rThal), and predefined regions of cortex (sections 8-11, i.e., between bregma +1.70 and +0.38) and hippocampus (sections 6-9. i.e., between bregma -1.58 and -1.82 respectively) corresponding with our pre-defined immunohistochemistry quantitation. % ID/g values were calculated for each ROI using the decay-corrected dose for each mouse at time of PET scan. Signal-to-background ratios were determined by dividing the uptake in cortex or hippocampus by uptake in the rThal. The rThal served as a reference region due to negligible TSPO staining and relative low PET signal in this region, which did not vary significantly between wild-type and APP L/S mice.
Ex Vivo Autoradiography
Following final PET/CT scans, n = 7 mice per treatment group were perfused with 0.9% sodium chloride solution (50 mL), brain tissue was embedded in optimal-cutting temperature compound (OCT, Tissue-Tek), and coronal sections (20 µm) were obtained for ex vivo autoradiography. Autoradiography was conducted using previously described methods [42] and anatomy of brain sections was confirmed by Nissl staining (cresyl violet acetate; Sigma Aldrich) using standard techniques. For quantitation of autoradiography images, five sections per mouse were analyzed. For each section, one region was drawn within the somatosensory cortex, thalamus, and hippocampus (between bregma +1.70 and -1.82 -corresponding to brain regions used for PET image analysis), resulting in a mean signal intensity value for each brain region within each section (normalized to area of region). For each mouse, the mean signal intensities (i.e., mean radiotracer uptake) of cortex and hippocampus were normalized to the mean signal intensity of rThal (region containing negligible TSPO). See Fig. S3 for evidence of negligible TSPO staining in rostral thalamus of 8.5-10 month old wild-type and APP L/S mice.
Plasma Free Fraction (fP)
Determination of the plasma free fraction (fP) for [ 18 F]GE-180 in 8.5-10 month old mice (n = 4 APP L/S -veh, n = 6 wild-type-veh, n = 4 APP L/S -LM11A-31, n = 5 wild-type-LM11A-31) was performed at room temperature with ultrafiltration units, according to previously described methods [43] .
Immunostaining and Quantitation
Free-floating 50 μm coronal sections were collected through the entire brain using Microm HM 450 sliding microtome (Thermo Scientific). For immunostaining following standard protocols, the following antibodies were used: rabbit anti-Iba1 (Wako; 1:2000) and rabbit anti-TSPO (Epitomics; 1:500). For visualization, sections were immersed in Vectastain Elite ABC kit (Vector Laboratories) followed by 0.05% 3,3-diaminobenzidine (Sigma) in TBS with 0.03% H2O2. All staining was performed in one single large batch and included all animals in this study (i.e., all four treatment groups were processed at the same time; wt-veh, wt-C31, APP-veh, and APP-C31).
For image acquisition of TSPO and Iba1-labelled microglia, digitized images were captured with Zeiss AxioImager M2 light microscope using Microlucida software v 11.03.1 and the exact same settings for all samples. For assessment of the cortex comprising the primary and secondary somatosensory areas of one hemisphere between bregma 1.70-0.38 mm according to the Franklin and Paxinos 3 rd edition mouse brain atlas, four coronal sections per mouse were analyzed (n = 8-10 mice per genotype-treatment group). In each section, two adjacent non-overlapping 10x fields (sample field 550um x 425um) were analyzed for a total of 8 fields per mouse. The same sample fields were analyzed for both Iba1 and TSPO stains. The average pixel intensity of TSPO staining was determined by UN-SCAN-IT software v6.1 (Silk Scientific Corporation). To reduce any variability during intensity quantification, background subtraction was used in UN-SCAN-IT and included subtracting the background region value for each image quantified to ensure the results were due to intensity differences rather than differences in background staining. To quantify percent area occupied by Iba1-labelled microglia from digitized images, histogram thresholding in ImageJ v 1.47 software was used. The thresholding was set manually to distinguish between dense immunostaining distinct from the background. For each mouse, a total of eight field values were averaged to yield one value measurement per mouse. For analysis of hippocampal Iba1 or TSPO burden, one 10x field covering the majority of the hippocampus in one hemisphere (sample field 550um x 425um) between bregma -1.58 and -1.82 mm was analyzed per section, for a total of four sections per mouse (n = 8-10 mice per genotype-treatment group). The same quantification methods were used for both cortex and hippocampal measurements of average pixel intensity for TSPO staining and percent area occupied by Iba1-labelled microglia. For each mouse, a total of four hippocampal field values were averaged to yield one value measurement per mouse. All staining, acquisition and analysis was performed by experimenter blind to animal genotype and treatment.
Statistical Analysis
The Wilcoxon-Mann-Whitney test was used to determine whether there were significant differences in cortical/hippocampal uptake between wild-type-veh and APP L/S -veh mice and APP L/S -veh and APP L/S -LM11A-31 mice for both PET and autoradiography data. The Student's t-test was used to determine whether there were significant differences between blocked versus unblocked dynamic PET imaging data, and fP data for each group of mice. We used Spearman's rank correlation to assess the relationship between TSPO/Iba1 staining and [ 18 F]GE-180-PET signal in cortex and hippocampus. Statistical analyses of data were performed using PRISM version 6.0d and significance was set at p<0.05. All data are presented as mean ± SEM. The outlier criterion was established as 2 standard deviations (STDEV) from the average. No outliers were observed in these studies. (Fig. 1) , we assessed the uptake and kinetics of [ 18 F]GE-180 via dynamic PET/CT imaging of 8.5-10 month old APP L/S mice (n = 6) and age-matched littermates (n = 6). APP L/S mice of this age are known to exhibit amyloid plaques and neuroinflammation in both cortex and hippocampus [37] . Time activity curves generated from these dynamic imaging studies ( Fig. 2A) showed markedly higher [ 18 F]GE-180 accumulation in cortex and hippocampus of APP L/S mice compared to age-matched wild-types (25 ± 1.74% higher uptake at 50-60 min post-injection, p=0.0042), and significant attenuation of PET signal in APP L/S mice (n = 4) pre-treated with 1 mg/kg of the blocking agent PK11195 (69% reduction at 50-60 min post-injection, p=0.001). These results demonstrate that [ 18 F]GE-180 has suitable specificity and sensitivity (signal-to-background) for detecting alterations in TSPO, and therefore microglial activation, in APP L/S mice of this age. Timeline and study design for evaluating TSPO-PET as an imaging biomarker strategy to monitor response to a novel AD therapeutic (i.e., LM11A-31) currently in clinical trials. Based on findings from the head-to-head comparison study, the most sensitive TSPO-PET ligand was selected for therapy monitoring studies. Baseline PET imaging of APP L/S mice with pathology and wild-type littermates (5.5-7 months of age) was performed just prior to commencing treatment with LM11A-31, and again at the conclusion of the study after mice had been treated daily with LM11A-31 for 3 months. Ex vivo autoradiography and histology were conducted immediately following the final PET imaging time-point. TSPO and Iba1 immunostaining were performed to investigate the relationship between TSPO-PET signal and levels of target (i.e., TSPO and activated microglia). (Fig. S4) .
Results
The rostral thalamus is a suitable pseudo-reference region for TSPO-PET imaging of AD mice.
To accurately measure subtle alterations in TSPO density in the brain with PET imaging, absolute quantitation using an input function or selection of a suitable reference region is usually required. The former involves arterial blood sampling or an image-derived input function using the left ventricle [44, 45] , whereas the latter requires identification of a region in the brain containing negligible levels of TSPO. Another consideration for the reference region approach is that radiotracer uptake and actual levels of TSPO in the reference structure should not differ between comparison groups. Since arterial blood sampling in mice is immensely challenging and TSPO is highly expressed in normal rodent and human myocardium, a reference region approach is preferred. To identify a suitable reference region in the brain of APP L/S and age-matched wild-type mice, we conducted an unbiased investigation of [ 18 F]GE-180 uptake in 15 different brain regions in both wild-type and APP L/S mice using an automated 3D brain atlas tool within VivoQuant image analysis software (Fig. 3A-B) . After comparing [ 18 F]GE-180 uptake in all brain regions automatically defined by the 3D atlas, we found the thalamus to have the lowest relative uptake and no significant difference between wild-type and APP L/S mouse groups (p=0.33), thus highlighting its suitability as a candidate reference region for studies with these mice. Subsequent immunohistochemical analysis revealed very low levels of TSPO staining throughout the entire thalamus of wild-type mice, some TSPO staining in the caudal thalamus (cThal) of APP L/S mice, and very low levels of staining in the rostral thalamus (rThal) of APP L/S mice (Fig. 3C) . Plots of [ 18 F]GE-180 uptake (% ID/g) in the rThal and cThal of wild-type and APP L/S mice (Fig. 3D) revealed no significant genotype difference in rThal uptake (p=0.53) and a trend toward higher [ 18 F]GE-180 uptake in the cThal of APP L/S mice (p=0.09). We also assessed the kinetics of [ 18 F]GE-180 in the rostral thalamus over the course of a 60-minute dynamic scan and confirmed that there were no significant differences between uptake in APP L/S mice and wild-types between 10-60 min (Fig. S5) . Taken together, these data demonstrate that the rThal can serve as a suitable pseudo-reference region for [ 18 F]GE-180-PET imaging of APP L/S and wild-type mice. Since the rThal is not completely devoid of TSPO, but instead contains very low levels of TSPO, it is considered a pseudo-reference region.
Next, we employed the use of the rThal as a pseudo-reference region -i.e., we divided cortical and hippocampal % ID/g values by rThal % ID/g values for each mouse (Fig. 3E) . The effect sizes between wild-type and APP L/S mice for the uptake ratios were slightly higher than that observed for % ID/g values (i.e., cortex/rThal: 26% vs. 25%; hippocampus/rThal: 22% vs. 21%), while the standard deviations and coefficient of variance for APP L/S mice were lower (Table. S1 ). These results suggest that using the rThal as a reference region, provides greater sensitivity and lower variability than % ID/g values, and thus further validate its use for subsequent [ 18 
[ 18 F]GE-180-PET and ex vivo autoradiography detect reduced microglial activation in AD mice treated with LM11A-31
Before commencing once daily oral gavage treatment of APP L/S and wild-type mice aged 5.5-7.0 months, with either LM11A-31 (50 mg/kg) or vehicle (veh), baseline [ 18 F]GE-180-PET scans were acquired for each mouse. Baseline imaging revealed significantly higher uptake in cortex and hippocampus of 5.5-7.0 month old APP L/S compared to wild-type mice (p=0.029), corresponding with pathology known to be present in these brain regions of APP L/S mice this age [36, 37] (Fig. S7) . Baseline % ID/g values were then used to randomize mice into four treatment groups -i.e., APP L/S -LM11A-31 (n = 8), APP L/S -veh (n = 9), wild-type-LM11A-31 (n = 11), and wild-type-veh (n = 10) -such that there were no significant differences in cortical or hippocampal Next we examined whether the plasma free fraction (fP), and therefore the percentage of [ 18 F]GE-180 available for binding, varied between 8.5-10 month old wild-type and APP L/S mice treated with either vehicle or LM11A-31. No significant differences in fP were found between treatment groups (i.e., APP L/S -veh: 15.2 ± 0.01%, wild-type-veh: 16.5 ± 0.02%, APP L/S -LM11A-31: 16.3 ± 0.02%, wild-type-LM11A-31: 17.0 ± 0.02%, n = 4-6 per group), indicating that neither genotype nor LM11A-31 treatment affected [ 18 F]GE-180 plasma protein binding in APP L/S and wild-type mice of this age (Fig. S9) .
To further investigate the accumulation of [ 18 F]GE-180 in specific brain regions we performed ex vivo autoradiography using 20 µm-thick coronal brain sections from these same mice after their final PET scans (n = 7 per group). The high spatial resolution of autoradiography combined with the anatomical information provided by Nissl staining of the same sections enabled clear visualization of [ 18 F]GE-180 accumulation in cortex and hippocampus of APP L/S mice (Fig. 5) . In support of the in vivo PET results, quantitative ex vivo brain autoradiography showed elevated [ 18 F]GE-180 accumulation in APP L/S -veh mice in regions known to contain activated microglia (cortex/rThal: 1.54 ± 0.06 vs 1.13 ± 0.03, p=0.0012; hippocampus/rThal: 1.42 ± 0.04 vs 1.21 ± 0.04, p=0.005), and a significant reduction of radiotracer uptake in APP L/S mice treated with LM11A-31 (cortex/rThal: 1.31 ± 0.05 vs 1.54 ± 0.06, p=0.015; hippocampus/rThal: 1.25 ± 0.02 vs 1.42 ± 0.04, p=0.0087). We also observed uptake in a region corresponding to the choroid plexus for both wild-type and APP L/S mice, qualitatively similar to our previously reported TSPO autoradiography studies with these mice [39] . The choroid plexus is known to contain moderate levels of TSPO in healthy human and rodent brains [46] , with these levels elevated in certain diseases [47] , and thus could be an important brain region to consider when monitoring the progression of AD and also for quantifying therapeutic response in AD patients. In order to assess whether [ 18 F]GE-180 signal correlated with levels of activated microglia and TSPO, we performed immunohistochemistry (Fig. 6 ) using harvested brain tissue from the same 8.5-10 month old mice used for PET imaging and autoradiography.
Quantitation of percent cortical/hippocampal area occupied by Iba1 staining (microglial marker) showed increased levels of activated microglia in APP L/S -veh compared to wild-type-veh mice (p=0.021, n = 7-8 per group), and significantly less activated microglia in APP L/S -LM11A-31 mice compared to APP L/S -veh (p=0.0001, n = 8). Likewise, the intensity of TSPO staining in cortex/hippocampus was found to be significantly greater in APP L/S -veh compared to wild-type-veh (p=0.0001, n = 7-8 per group) and APP L/S -LM11A-31 mice (p=0.0001, n = 8 per group). 
Discussion
AD is the most common neurodegenerative disorder, and its prevalence is expected to triple by 2050. At present, there is no approved therapeutic that can halt or reverse disease progression, and all efforts to develop and translate such treatments to the clinic have been unsuccessful thus far. Possible reasons for these disappointing results include the limited number of translatable biomarkers useful in both mouse models and humans, and the relatively small role that appropriate biomarkers have played in the drug development process.
Increasing evidence suggests that microglial activation takes place early in AD, before the formation of amyloid plaques, and serves as a third rail in the development of this disease [48] . Additionally, genome-wide association studies (GWAS) of late onset AD highlight a dominant role for microglial malfunction in increasing risk of AD. Moreover, a recent TSPO-PET study reported by Hamelin and colleagues demonstrated that neuroinflammation is present at the prodromal stage of AD and that it may even play a protective role in these early stages -due to the high TSPO-PET signal in slow decliners versus rapid decliners observed in this study [22] . Together, these data highlight the importance of developing and evaluating therapeutics that modulate microglial responses, and also support the need for a non-invasive technique for tracking microglial activation longitudinally in AD. In the current work, we set out to evaluate the TSPO PET agent [ 18 F]GE-180 for its ability to detect microglial activation at different stages of disease progression and monitor response to LM11A-31 in a well-established AD mouse model. [29] , likely resulting in a higher degree of non-specific binding for [ 18 F]PBR06 and therefore lower signal-to-background. Another explanation for this disparity may be due to differences in how and where these two radiotracers bind and interact with various conformational and/or oligomeric states of TSPO in different diseases [50] . Since To minimize unwanted intra-/inter-subject and PET scanner variability, and maximize one's ability to robustly detect small group differences, the selection of an appropriate reference region for PET image analysis is critical. Previous studies have reported the use of the striatum or cerebellum as possible reference regions for TSPO-PET studies of AD patients and mice [25, 51] . In our studies, however, we determined that the cerebellum had high uptake of [ 18 F]GE-180 and that accumulation in the striatum varied significantly between wild-type and APP L/S micethus negating the use of these structures as reference regions. Our unbiased analysis of [ 18 F]GE-180 uptake in 15 different mouse brain structures identified the rostral thalamus as a region that contained relatively low radiotracer uptake that did not vary between APP L/S and wild-type mice. Interestingly, Lemere and colleagues also found the thalamus to be a suitable reference region (via immunohistological analyses) for their TSPO-PET studies in a different AD mouse model (APP-PS1), however they used a small region of the caudal thalamus for PET uptake ratio calculations [52] . Our histological analyses revealed that the caudal thalamus contained slightly higher levels of TSPO in APP L/S mice compared to wild-types, whereas there was no difference in TSPO levels in the rostral thalamus (between the ages of 5.5-10 months -i.e., the stages of disease evaluated in this study). We systematically defined the rostral thalamus as a suitable pseudo-reference region according to both PET imaging data and immunohistochemistry analyses. The combination of these two approaches yielded a reference region and subsequent uptake ratio values that robustly removed unwanted intra-/inter-subject variance but not the effects of the disease and/or its progression. Further studies will be needed to validate the use of the rostral thalamus as a reference region at later stages of disease (i.e., after 10 months) in APP L/S mice.
Results from our therapy monitoring studies demonstrate the ability of [ 18 F]GE-180 to not only detect a response to LM11A-31 (i.e., reduction in microglial activation) with high sensitivity and specificity, but to also identify alterations in microglial activation in living AD mice at different stages of disease. We observed significantly higher uptake of [ 18 F]GE-180 in the cortex and hippocampus of APP L/S mice as early as 5.5-7.0 months of age compared to wild-type littermates, and an even greater level of radiotracer uptake in APP L/S mice 8.5-10.0 months of age. Although the differences detected were small (i.e., 12-13% for younger APP L/S mice and 21-26% for older APP L/S mice), they are in line with the magnitude of brain regional differences reported for TSPO-PET imaging of AD patients compared to healthy controls using other TSPO radiotracers [26] . Autoradiographic analysis of brain sections following perfusion (i.e., after removing unbound/intravascular radioactivity from the brain) further confirmed elevated binding of [ 18 F]GE-180 in cortex and hippocampus of APP L/S mice compared to wild-types, and a significantly lower signal in the same brain regions of APP L/S mice treated with LM11A-31. Both PET and autoradiography data was corroborated by immunohistochemistry results showing that TSPO and Iba1 expression were elevated in the cortex and hippocampus of APP L/S -veh mice compared to wild-type-veh, wild-type-LM11A-31, and APP L/S -LM11A-31 mouse groups.
To date, there have been a very limited number of studies involving therapy monitoring with TSPO-PET ligands, and in fact our current study appears to be the first report of using in vivo TSPO-PET imaging for monitoring response to an AD therapeutic. Roberts and colleagues reported an ex vivo autoradiography study whereby the tritiated TSPO radioligand [ 3 H]DPA-713 was assessed for its ability to detect response to a PPARγ agonist in TASTPM mice [53] . Although there was no in vivo PET imaging, and the therapeutic response in this study was not significant (histologically or otherwise), the authors emphasized the potential of TSPO radioligands for assessing anti-inflammatory therapeutics before translation to AD patients.
Our future studies will involve assessing the use of [ 18 F]GE-180 for monitoring alterations in microglial activation after treatment with different therapeutics that directly or indirectly affect neuroinflammation in mouse models of AD -for example, minocycline [11] , non-steroidal anti-inflammatories [13] , and/or prostaglandin EP2 receptor antagonists [54, 55] . In addition, since [ 18 F]GE-180 has already been approved for human use and has undergone favorable first-in-man studies, [ 18 F]GE-180-PET could serve as a surrogate endpoint in upcoming clinical trials of LM11A-31 in AD patients. In these studies, we will assess how well the [ 18 F]GE-180-PET signal correlates with cognitive status and other biomarkers. We plan to implement the optimized scanning protocol (90 min) and kinetic modeling strategy (reversible two-tissue compartment model) reported by Fan and colleagues in their paper detailing the first human PET study with [ 18 F]GE-180 [56] . As part of these future studies, we will compare [ 18 optimal-cutting temperature; TBS: Tris-buffered saline; STDEV: standard deviation; SEM: standard error of mean.
